WallStSmart

Bio-Rad Laboratories Inc (BIO-B)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 712% more annual revenue ($20.63B vs $2.54B). GEHC leads profitability with a 10.1% profit margin vs -85.2%. BIO-B appears more attractively valued with a PEG of 1.21. GEHC earns a higher WallStSmart Score of 60/100 (C+).

BIO-B

Hold

37

out of 100

Grade: F

Growth: 2.0Profit: 3.5Value: 6.7Quality: 8.5
Piotroski: 5/9Altman Z: 2.31

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BIO-B.

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIO-B2 strengths · Avg: 9.5/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.209/10

Conservative balance sheet, low leverage

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

BIO-B4 concerns · Avg: 1.8/10
Return on EquityProfitability
-27.5%2/10

ROE of -27.5% — below average capital efficiency

Revenue GrowthGrowth
-4.2%2/10

Revenue declined 4.2%

EPS GrowthGrowth
-83.0%2/10

Earnings declined 83.0%

Profit MarginProfitability
-85.2%1/10

Currently unprofitable

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BIO-B

The strongest argument for BIO-B centers on Price/Book, Debt/Equity. PEG of 1.21 suggests the stock is reasonably priced for its growth.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : BIO-B

The primary concerns for BIO-B are Return on Equity, Revenue Growth, EPS Growth.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

BIO-B profiles as a turnaround stock while GEHC is a value play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

GEHC is growing revenue faster at 7.1% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bio-Rad Laboratories Inc

HEALTHCARE · MEDICAL DEVICES · USA

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?